Drug Interactions between FemSeven Sequi Phase I and lorlatinib

Consumer information for this interaction is not currently available.

ADDITIONAL CONTRACEPTION RECOMMENDED: Concomitant use with lorlatinib may decrease the plasma concentrations and efficacy of contraceptive hormones. In vitro studies show that lorlatinib is an inducer of CYP450 3A, the isoenzyme primarily responsible for the metabolic clearance of sex hormones. The use of hormonal contraceptives during treatment with lorlatinib can result in contraception failure. Lorlatinib can also cause embryo-fetal harm when administered to a pregnant woman.

MANAGEMENT: Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with lorlatinib. Since the use of lorlatinib is likely associated with embryo-fetal harm, it is particularly important that patients not become pregnant during treatment. Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with lorlatinib. Women of childbearing potential should use a highly effective, non-hormonal method of contraception during treatment with lorlatinib and for 6 months after the last dose. Male patients with female partners of reproductive potential should use effective contraception during treatment with lorlatinib and for 3 months after the last dose.